Literature DB >> 16700040

Cerebral metastases pathology after radiosurgery: a multicenter study.

Gyorgy T Szeifert1, Dave S Atteberry, Douglas Kondziolka, Marc Levivier, L Dade Lunsford.   

Abstract

BACKGROUND: To the authors' knowledge, comprehensive human pathologic investigations that explore fundamental radiosurgical effects on metastatic brain tumors are sparse in the literature. The objective of this study was to analyze histopathologic findings in a set of clinically recurrent cerebral metastases after patients underwent stereotactic radiosurgery (SRS).
METHODS: In a series of 7500 patients who underwent radiosurgery, 2020 patients (27%) harbored cerebral metastases. Eighteen of 2020 patients (0.9%) underwent subsequent craniotomy for tumor removal anywhere from 1 month to 59 months after they received high-dose irradiation. Histologic and immunohistochemical investigations were performed on the surgically resected tissue specimens. These specimens were within the radiosurgical treatment volume of the metastatic tumor.
RESULTS: Light microscopy revealed 3 basic categories of histologic responses: acute-type, subacute-type, and chronic-type tissue reactions. A moderate-to-intense inflammatory cell reaction was seen in the tissue responses of well controlled neoplasms (i.e., in patients who had neoplasms that required craniotomy for recurrent disease > 5 months after SRS), whereas the inflammatory reaction was missing or sparse in poorly controlled neoplasms (patients who required craniotomy for recurrent disease < 5 months after SRS). This reaction was seen within the irradiated tumor volume and not in the peritumoral area nor in areas remote from the radiosurgical treatment volume. Immunohistochemical characterization demonstrated the presence of prominent CD68-positive macrophage and CD3-positive T-lymphocyte populations. A progressively severe vasculopathy also was observed with increasing time after radiosurgery.
CONCLUSIONS: Although causality has not been established, a brisk inflammatory response and more severe vasculopathy were observed in lesions in which recurrences were more delayed. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700040     DOI: 10.1002/cncr.21946

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Gamma Knife treatment of recurrent CNS metastases of pancreatic origin: a case report and review of the literature.

Authors:  Subha Perni; Tony J Wang; Jerry Lesser; Christopher Mandigo; Steven R Isaacson; David P Horowitz
Journal:  CNS Oncol       Date:  2017-04

2.  Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.

Authors:  Susan C Pannullo; Justin F Fraser; Jennifer Moliterno; William Cobb; Philip E Stieg
Journal:  J Neurooncol       Date:  2010-12-09       Impact factor: 4.130

3.  Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors:  Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

4.  Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology.

Authors:  Jay S Detsky; Julia Keith; John Conklin; Sean Symons; Sten Myrehaug; Arjun Sahgal; Chinthaka C Heyn; Hany Soliman
Journal:  J Neurooncol       Date:  2017-07-03       Impact factor: 4.130

5.  Use of radiomics for the prediction of local control of brain metastases after stereotactic radiosurgery.

Authors:  Andrei Mouraviev; Jay Detsky; Arjun Sahgal; Mark Ruschin; Young K Lee; Irene Karam; Chris Heyn; Greg J Stanisz; Anne L Martel
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

6.  Predicting treatment related imaging changes (TRICs) after radiosurgery for brain metastases using treatment dose and conformality metrics.

Authors:  B Frazier Taylor; Jonathan P Knisely; Jack M Qian; James B Yu; Veronica L Chiang
Journal:  J Radiosurg SBRT       Date:  2016

7.  Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?

Authors:  Alexander Romagna; Marcus Unterrainer; Christine Schmid-Tannwald; Matthias Brendel; Jörg-Christian Tonn; Silke Birgit Nachbichler; Alexander Muacevic; Peter Bartenstein; Friedrich-Wilhelm Kreth; Nathalie Lisa Albert
Journal:  Radiat Oncol       Date:  2016-10-21       Impact factor: 3.481

Review 8.  Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.

Authors:  Sameera S Kumar; Kristin A Higgins; Ronald C McGarry
Journal:  Front Oncol       Date:  2017-09-04       Impact factor: 6.244

Review 9.  Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases.

Authors:  Balamurugan Vellayappan; Char Loo Tan; Clement Yong; Lih Kin Khor; Wee Yao Koh; Tseng Tsai Yeo; Jay Detsky; Simon Lo; Arjun Sahgal
Journal:  Front Oncol       Date:  2018-09-28       Impact factor: 6.244

10.  Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases.

Authors:  Zhou Su; Lin Zhou; Jianxin Xue; You Lu
Journal:  Chin J Cancer Res       Date:  2020-08       Impact factor: 4.026

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.